Literature DB >> 27664262

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

B Escudier1, C Porta2, M Schmidinger3, N Rioux-Leclercq4, A Bex5, V Khoo6, V Gruenvald7, A Horwich8.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27664262     DOI： 10.1093/annonc/mdw328

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  124 in total

1.  Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

Authors:  Nizar M Tannir; Robert A Figlin; Martin E Gore; M Dror Michaelson; Robert J Motzer; Camillo Porta; Brian I Rini; Caroline Hoang; Xun Lin; Bernard Escudier
Journal:  Clin Genitourin Cancer       Date:  2017-06-20       Impact factor: 2.872

Review 2.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

Review 3.  A review of guidelines for lung cancer.

Authors:  Paolo Bironzo; Massimo Di Maio
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.

Authors:  Roberto Iacovelli; Chiara Ciccarese; Giuseppe Fornarini; Francesco Massari; Davide Bimbatti; Claudia Mosillo; Sara Elena Rebuzzi; Vincenzo Di Nunno; Massimiliano Grassi; Emanuela Fantinel; Andrea Ardizzoni; Giampaolo Tortora
Journal:  Br J Clin Pharmacol       Date:  2019-03-31       Impact factor: 4.335

5.  [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]

Authors:  N Gilbert; A S Merseburger; M W Kramer
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 6.  Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.

Authors:  Bulent Cetin; Alim Kosar
Journal:  Int Urol Nephrol       Date:  2019-08-29       Impact factor: 2.370

Review 7.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Authors:  Mohammad H Bagheri; Mark A Ahlman; Liza Lindenberg; Baris Turkbey; Jeffrey Lin; Ali Cahid Civelek; Ashkan A Malayeri; Piyush K Agarwal; Peter L Choyke; Les R Folio; Andrea B Apolo
Journal:  Urol Oncol       Date:  2017-05-12       Impact factor: 3.498

8.  A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma.

Authors:  Michio Kimura; Eiseki Usami; Hitomi Teramachi; Tomoaki Yoshimura
Journal:  Mol Clin Oncol       Date:  2020-01-16

Review 9.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

10.  Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.

Authors:  S Nazha; S Tanguay; A Kapoor; M Jewett; C Kollmannsberger; L Wood; G Bjarnason; D Heng; D Soulières; N Reaume; N Basappa; E Lévesque; A Dragomir
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.